• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

基于循环游离DNA检测肿瘤抑制基因拷贝数缺失及其在转移性前列腺癌中的临床意义

Circulating Cell-Free DNA-Based Detection of Tumor Suppressor Gene Copy Number Loss and Its Clinical Implication in Metastatic Prostate Cancer.

作者信息

Dong Xiaoxi, Zheng Tiantian, Zhang Minhua, Dai Chao, Wang Lili, Wang Lei, Zhang Ruipeng, Long Yuan, Wen Danyi, Xie Feng, Zhang Yue, Huang Yong, Dong Jianguo, Liu Huan, Du Pan, King Bonnie L, Tan Winston, Jia Shidong, Lu Chris X, Kohli Manish, Wang Haitao, Yu Jianjun

机构信息

Predicine Inc., Hayward, CA, United States.

Department of Translational Medicine, Laekna Therapeutics Shanghai Co., Ltd., Shanghai, China.

出版信息

Front Oncol. 2021 Aug 24;11:720727. doi: 10.3389/fonc.2021.720727. eCollection 2021.

DOI:10.3389/fonc.2021.720727
PMID:34504797
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8422845/
Abstract

Current liquid biopsy assays lack sufficient sensitivity to detect copy number loss, which limits the interrogation of critical tumor suppressor gene deletions during cancer progression and treatment. Here we describe a liquid biopsy assay with improved sensitivity for detection of copy number loss in blood samples with low levels of circulating tumor DNA, and demonstrate its utility by profiling , , and genetic loss in metastatic prostate cancer patients.

摘要

目前的液体活检检测方法在检测拷贝数缺失方面缺乏足够的灵敏度，这限制了在癌症进展和治疗过程中对关键肿瘤抑制基因缺失的研究。在此，我们描述了一种液体活检检测方法，该方法对检测低水平循环肿瘤DNA的血样中的拷贝数缺失具有更高的灵敏度，并通过分析转移性前列腺癌患者的 、 和 基因缺失来证明其效用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59e5/8422845/339315f4f3ef/fonc-11-720727-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59e5/8422845/baff1beb91cc/fonc-11-720727-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59e5/8422845/339315f4f3ef/fonc-11-720727-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59e5/8422845/baff1beb91cc/fonc-11-720727-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59e5/8422845/339315f4f3ef/fonc-11-720727-g002.jpg

相似文献

1
Circulating Cell-Free DNA-Based Detection of Tumor Suppressor Gene Copy Number Loss and Its Clinical Implication in Metastatic Prostate Cancer.基于循环游离DNA检测肿瘤抑制基因拷贝数缺失及其在转移性前列腺癌中的临床意义
Front Oncol. 2021 Aug 24;11:720727. doi: 10.3389/fonc.2021.720727. eCollection 2021.
2
Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.局部和转移性前列腺癌中 TP53、PTEN 和 RB1 肿瘤抑制因子的复合基因组改变。
Eur Urol. 2019 Jul;76(1):89-97. doi: 10.1016/j.eururo.2018.11.045. Epub 2018 Dec 12.
3
Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer.联合检测游离 DNA 和 RNA 的雄激素受体：一种新型多分析物液体活检检测在转移性前列腺癌中的临床应用。
Eur Urol. 2020 Aug;78(2):173-180. doi: 10.1016/j.eururo.2020.03.044. Epub 2020 May 30.
4
Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.循环肿瘤 DNA 丰度及其在初发性转移性前列腺癌中的潜在应用。
Eur Urol. 2019 Apr;75(4):667-675. doi: 10.1016/j.eururo.2018.12.042. Epub 2019 Jan 10.
5
Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer.基于免疫组织化学的转移性去势抵抗性前列腺癌雄激素受体状态和 AR 缺失表型评估。
Prostate Cancer Prostatic Dis. 2020 Sep;23(3):507-516. doi: 10.1038/s41391-020-0214-6. Epub 2020 Feb 24.
6
Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) Environments.在临床实验室改进修正案（CLIA）环境中对侵袭性变异型前列腺癌分子特征的评估。
Cancers (Basel). 2023 Dec 14;15(24):5843. doi: 10.3390/cancers15245843.
7
TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer.循环肿瘤 DNA 中 TP53 功能获得性突变与转移性去势抵抗性前列腺癌男性患者
Clin Genitourin Cancer. 2020 Apr;18(2):148-154. doi: 10.1016/j.clgc.2019.10.022. Epub 2019 Nov 6.
8
Significance of and Co-loss in Aggressive Prostate Cancer Progression.和在侵袭性前列腺癌进展中的共同缺失的意义。
Clin Cancer Res. 2020 Apr 15;26(8):2047-2064. doi: 10.1158/1078-0432.CCR-19-1570. Epub 2019 Dec 3.
9
Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients.中国转移性乳腺癌患者癌症基因突变特征分析
Front Oncol. 2020 Jun 30;10:1023. doi: 10.3389/fonc.2020.01023. eCollection 2020.
10
Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis.基于下一代测序和单细胞全基因组拷贝数变异分析的染色体不稳定性评估
PLoS One. 2016 Nov 16;11(11):e0165089. doi: 10.1371/journal.pone.0165089. eCollection 2016.

引用本文的文献

1
Retrospective comparison between breast cancer tissue- and blood-based next-generation sequencing results in detection of PIK3CA, AKT1, and PTEN alterations.基于乳腺癌组织和血液的二代测序结果在检测PIK3CA、AKT1和PTEN改变方面的回顾性比较。
Breast Cancer Res. 2025 Jul 1;27(1):122. doi: 10.1186/s13058-025-02055-0.
2
Circulating Tumor DNA in Genitourinary Cancers: Detection, Prognostics, and Therapeutic Implications.泌尿生殖系统癌症中的循环肿瘤DNA：检测、预后及治疗意义
Cancers (Basel). 2024 Jun 20;16(12):2280. doi: 10.3390/cancers16122280.
3
Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator.

本文引用的文献

1
Plasma Cell-Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer.转移性去势抵抗性前列腺癌中 PTEN-PI3K-AKT 通路异常的游离血浆 DNA 分析。
JCO Precis Oncol. 2021 Apr 6;5. doi: 10.1200/PO.20.00424. eCollection 2021.
2
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.基于循环肿瘤 DNA 改变的临床和基因组分析在转移性激素敏感型和去势抵抗性前列腺癌中的应用。
EBioMedicine. 2020 Apr;54:102728. doi: 10.1016/j.ebiom.2020.102728.
3
A Prospective Correlation of Tissue Histopathology With Nucleic Acid Yield in Metastatic Castration-Resistant Prostate Cancer Biopsy Specimens.
支持肿瘤学中的生物标志物驱动疗法：基因组测试成本计算器。
Oncologist. 2023 May 8;28(5):e242-e253. doi: 10.1093/oncolo/oyad005.
4
Liquid Biopsy in Prostate Cancer Management-Current Challenges and Future Perspectives.前列腺癌管理中的液体活检——当前挑战与未来展望
Cancers (Basel). 2022 Jul 4;14(13):3272. doi: 10.3390/cancers14133272.
5
Biofluids manipulation methods for liquid biopsy in minimally-invasive assays.用于微创检测中液体活检的生物流体处理方法
MethodsX. 2022 Jun 17;9:101759. doi: 10.1016/j.mex.2022.101759. eCollection 2022.
转移性去势抵抗性前列腺癌活检标本中组织病理学与核酸产量的前瞻性相关性
Mayo Clin Proc Innov Qual Outcomes. 2019 Feb 26;3(1):14-22. doi: 10.1016/j.mayocpiqo.2018.12.005. eCollection 2019 Mar.
4
Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.局部和转移性前列腺癌中 TP53、PTEN 和 RB1 肿瘤抑制因子的复合基因组改变。
Eur Urol. 2019 Jul;76(1):89-97. doi: 10.1016/j.eururo.2018.11.045. Epub 2018 Dec 12.
5
The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers.COSMIC 癌症基因目录：描述所有人类癌症中的遗传功能障碍。
Nat Rev Cancer. 2018 Nov;18(11):696-705. doi: 10.1038/s41568-018-0060-1.
6
Frequent mutation of the untranslated region in prostate cancer.前列腺癌中非编码区的频繁突变。
Commun Biol. 2018 Aug 24;1:122. doi: 10.1038/s42003-018-0128-1. eCollection 2018.
7
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.循环肿瘤 DNA 基因组学与前列腺癌对阿比特龙和恩杂鲁胺的耐药性相关。
Cancer Discov. 2018 Apr;8(4):444-457. doi: 10.1158/2159-8290.CD-17-0937. Epub 2018 Jan 24.
8
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.SOX2促进TP53和RB1缺陷型前列腺癌中的谱系可塑性和抗雄激素耐药性。
Science. 2017 Jan 6;355(6320):84-88. doi: 10.1126/science.aah4307.
9
Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer.尿液游离DNA中的拷贝数变异作为晚期前列腺癌的生物标志物
Oncotarget. 2016 Jun 14;7(24):35818-35831. doi: 10.18632/oncotarget.9027.
10
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer.前列腺癌中对雄激素受体抑制剂耐药的新机制
Nat Rev Cancer. 2015 Dec;15(12):701-11. doi: 10.1038/nrc4016. Epub 2015 Nov 13.